Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study

<i>Background</i>: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA therapy are still far from definitive. <i>Objective</i>: The goal of this study is to add new real-world data o...

詳細記述

書誌詳細

主要な著者:	Marino Paroli, Andrea Becciolini, Elena Bravi, Romina Andracco, Valeria Nucera, Simone Parisi, Francesca Ometto, Federica Lumetti, Antonella Farina, Patrizia Del Medico, Matteo Colina, Alberto Lo Gullo, Viviana Ravagnani, Palma Scolieri, Maddalena Larosa, Marta Priora, Elisa Visalli, Olga Addimanda, Rosetta Vitetta, Alessandro Volpe, Alessandra Bezzi, Francesco Girelli, Aldo Biagio Molica Colella, Rosalba Caccavale, Eleonora Di Donato, Giuditta Adorni, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Ilaria Platè, Natalia Mansueto, Aurora Ianniello, Enrico Fusaro, Maria Chiara Ditto, Vincenzo Bruzzese, Dario Camellino, Gerolamo Bianchi, Francesca Serale, Rosario Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Roberta Foti, Massimo Reta, Alessia Fiorenza, Guido Rovera, Antonio Marchetta, Maria Cristina Focherini, Fabio Mascella, Simone Bernardi, Gilda Sandri, Dilia Giuggioli, Carlo Salvarani, Veronica Franchina, Francesco Molica Colella, Giulio Ferrero, Alarico Ariani
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2023-08-01
シリーズ:	Medicina
主題:	tofacitinib Janus kinase inhibitors rheumatoid arthritis drug retention rate
オンライン･アクセス:	https://www.mdpi.com/1648-9144/59/8/1480
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!